Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.

Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...

There's a huge percentage of the US population that isn't getting access to these medications’: Novo Nordisk makes ...

Novo Nordisk shares are experiencing a significant decline amidst intensified investor concerns over its competitiveness in ...

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

Novo is paying up to $1 billion for a “non-incretin” medicine that might boost Wegovy’s effects. Elsewhere, Arbutus laid off ...